This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
VKTX Stock Jumps on Phase I Study Initiation for New Obesity Drug
by Zacks Equity Research
Viking Therapeutics jumps after it starts its first human study of VK3019, expanding its obesity pipeline with a second candidate alongside its lead program, VK2735.
VKTXNegative Net Change NVOPositive Net Change LLYNegative Net Change
biotechs medical pharmaceuticals
Reasons Why Investors Should Consider Betting on Indivior Stock
by Zacks Equity Research
INDV's Sublocade reaches 500,000+ U.S. patients. Management expects faster 2026 growth through cost optimization and strong execution.
INDVNegative Net Change AMRNNegative Net Change LQDANegative Net Change IMCRNegative Net Change
biotechs
Gilead Wins EC Approval to Expand Trodelvy's Label in Metastatic TNBC
by Zacks Equity Research
Gilead secures EC approval to expand Trodelvy into first-line metastatic TNBC, marking a new treatment option and broadening its oncology reach.
GILDNegative Net Change MRKNegative Net Change LQDANegative Net Change IMCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
RVMD Starts Treatment in Phase III Pancreatic Cancer Study on Zoldonrasib
by Zacks Equity Research
Revolution Medicines launches a phase III study of zoldonrasib plus chemotherapy in first-line metastatic PDAC harboring RAS G12D mutations.
RVMDNegative Net Change LQDANegative Net Change IMCRNegative Net Change INDVNegative Net Change
biotechs
GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH
by Zacks Equity Research
Galectin stock rises following FDA alignment on key elements of belapectin's phase III MASH cirrhosis program, clarifying a potential path toward full approval.
GALTNegative Net Change LQDANegative Net Change IMCRNegative Net Change INDVNegative Net Change
biotechnology biotechs medical pharmaceuticals
New Strong Buy Stocks for June 24th
by Zacks Equity Research
BY, NVGS, NBIX, TFII and BG have been added to the Zacks Rank #1 (Strong Buy) List on June 24th, 2026.
BGPositive Net Change NBIXNegative Net Change NVGSPositive Net Change BYPositive Net Change TFIINegative Net Change
biotechs finance medical
Biotech's Silent Resurgence (5-Year Base Breakout)
by Andrew Rocco
The biotech sector's fundamentals are shifting rapidly-and the smartest money on Wall Street is already quietly rotating into the sector.
NVSNegative Net Change PFENegative Net Change LLYNegative Net Change IBBNegative Net Change
biotechnology biotechs
Regeneron's Applications for gMG Drug Accepted by FDA and EMA
by Zacks Equity Research
Regeneron's cemdisiran won FDA Priority Review and EMA filing acceptance for gMG, backed by phase III data and a potentially unique dosing schedule.
REGNNegative Net Change SNYNegative Net Change ALNYNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
EXEL Down on Colorectal Cancer Study Data on Zanzalintinib
by Zacks Equity Research
Exelixis falls after STELLAR-303 misses statistical significance in overall survival for a key colorectal cancer subgroup, raising approval uncertainty.
RHHBYNegative Net Change MRKNegative Net Change EXELNegative Net Change NTRANegative Net Change
biotechnology biotechs medical pharmaceuticals
Biotech ETFs Put Up Strong Show in 1H 2026: More Gains Ahead?
by Sanghamitra Saha
Biotech ETFs are surging in 2026 as a friendlier FDA, strong M&A activity and AI-driven drug discovery fuel optimism for more upside.
BBCNegative Net Change ARKGNegative Net Change GNOMNegative Net Change IDNANegative Net Change
biotechs etfs